South Korea's HLB Pep wins $500,000 clinical API manufacturing contract
South Korean peptide manufacturer HLB Pep has secured a KRW666 million (approximately $500,000) contract with Skinmed to develop and manufacture an active pharmaceutical ingredient (API) for Phase II clinical trials.
The agreement, signed on November 19 and disclosed in a regulatory filing on November 20, runs through September 30, 2028.
The contract value, excluding VAT, represents 13.42% of HLB Pep's reported 2025 revenue, with payments linked to progress under the agreement.
HLB Pep will supply the API through its own domestic manufacturing operations rather than subcontracting production.
The company did not disclose the identity of the molecule, the manufacturing location or anticipated production volumes. Contract value and duration may change as development progresses.